Document is current
Any future updates will be listed below
-
Authors
Xue, Kanmin
Jolly, Jasleen K http://orcid.org/0000-0001-9878-4621
Barnard, Alun R. http://orcid.org/0000-0002-0662-1073
Rudenko, Anna
Salvetti, Anna P. http://orcid.org/0000-0002-5513-2241
Patrício, Maria I. http://orcid.org/0000-0003-3875-1400
Edwards, Thomas L. http://orcid.org/0000-0003-0238-7416
Groppe, Markus
Orlans, Harry O.
Tolmachova, Tanya
Black, Graeme C.
Webster, Andrew R.
Lotery, Andrew J. http://orcid.org/0000-0001-5541-4305
Holder, Graham E.
Downes, Susan M.
Seabra, Miguel C.
MacLaren, Robert E.
- License Information
-
More Information
Article History
Received: 25 April 2018
Accepted: 6 August 2018
First Online: 8 October 2018
Competing interests
: R.E.M.: scientific cofounder of Nightstar Therapeutics Inc.—a gene therapy company established by the University of Oxford and originally funded by the Wellcome Trust through Syncona Partners Ltd. A.R.B., G.C.B., A.J.L., G.C.B. and M.C.S.: consulting or on advisory board for Nightstar Therapeutics Inc. M.I.P., M.C.S. and R.E.M.: named inventors on patents relating to choroideremia gene therapy owned by the University of Oxford and Nightstar Therapeutics Inc. R.E.M., A.J.L. and G.C.B.: scientific advisory board to Spark Therapeutics Inc. The companies had no role in the conduct of this university-sponsored clinical trial, nor in the interpretation of the data, nor in the writing of the results. The views expressed are those of the authors and not necessarily those of the Wellcome Trust, the National Health Service, the NIHR or the UK Department of Health.
